Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)
Namrata Singh, Vithal Madhira, Chen Hu, Amy L. Olex, Timothy Bergquist, Kathryn C. Fitzgerald, Jared D. Huling, Rena C. Patel, Jasvinder A. Singh
Topics & Concepts
MedicineRheumatoid arthritisRituximabCoronavirus disease 2019 (COVID-19)Retrospective cohort studyCohortInternal medicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakImmunologyCohort studyAntirheumatic AgentsVirologyAntibodyDiseaseInfectious disease (medical specialty)OutbreakRheumatoid Arthritis Research and TherapiesCOVID-19 Clinical Research StudiesSpondyloarthritis Studies and Treatments